MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, CADL had $17,227K increase in cash & cash equivalents over the period. -$38,898K in free cash flow.

Cash Flow Overview

Change in Cash
$17,227K
Free Cash flow
-$38,898K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from term loan, net of ...
    • Proceeds from issuance of common...
    • Proceeds from sale of common sto...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Principal payments on term loan ...
    • Change in fair value of warrant ...
    • Others

Cash Flow
2025-12-31
Net loss
-38,182
Depreciation expense
845
Impairment of fixed assets
90
Loss on the sale and disposal of fixed assets
-306
Non-cash stock compensation expense
3,817
Non-cash lease expense
321
Non-cash interest expense
138
Change in fair value of warrant liabilities
-8,199
Accretion of debt discount
360
Prepaid expenses and other current assets
508
Other assets
24
Accounts payable
802
Accrued expenses
2,254
Deferred income
178
Lease liability
-509
Net cash used in operating activities
-38,311
Purchase of fixed assets
587
Proceeds from the sale of fixed assets
27
Net cash used in investing activities
-560
Proceeds from term loan, net of issuance costs
47,946
Proceeds from issuance of common stock in registered direct offering, net of issuance costs
14,331
Proceeds from sale of common stock through at-the-market offerings, net of issuance costs
5,038
Proceeds from option exercises
516
Principal payments on term loan payable to a bank
-11,733
Net cash provided by financing activities
56,098
Net increase in cash, cash equivalents and restricted cash
17,227
Cash, cash equivalents and restricted cash at beginning of period
102,920
Cash, cash equivalents and restricted cash at end of period
120,147
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from term loan,net of issuance...$47,946K Proceeds from issuance ofcommon stock in...$14,331K Proceeds from sale ofcommon stock through...$5,038K Proceeds from optionexercises$516K Net cash provided byfinancing activities$56,098K Canceled cashflow$11,733K Net increase incash, cash...$17,227K Canceled cashflow$38,871K Principal payments on termloan payable to a bank-$11,733K Non-cash stockcompensation expense$3,817K Accrued expenses$2,254K Depreciation expense$845K Accounts payable$802K Accretion of debt discount$360K Non-cash lease expense$321K Loss on the sale anddisposal of fixed assets-$306K Deferred income$178K Non-cash interestexpense$138K Impairment of fixed assets$90K Proceeds from the sale offixed assets$27K Net cash used inoperating activities-$38,311K Net cash used ininvesting activities-$560K Canceled cashflow$9,111K Canceled cashflow$27K Net loss-$38,182K Change in fair value ofwarrant liabilities-$8,199K Purchase of fixed assets$587K Lease liability-$509K Prepaid expenses andother current assets$508K Other assets$24K

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics, Inc. (CADL)